Rx Palladia 50mg x 30

Rx Palladia 50mg x 30 (toceranib phosphate) Tablets Antineoplastic PALLADIA tablets are indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs. For oral use in dogs only. This item requires a valid veterinarian's prescription. - CAUTIONS/WARNINGS:PALLADIA may cause vascular dysfunction which can lead to edema and thromboembolism including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis wait at least 3 days after stopping drug before performing surgery.

Do not use in dogs used for breeding or for pregnant or lactating bitches.

Potential Side Effects:
Diarrhea appetite loss lameness weight loss bloody stool

Serious and sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in dogs treated with PALLADIA (see Adverse Reactions). If gastrointestinal ulceration is suspected stop drug administration and treat appropriately.

Human warnings:

NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Children should not come in contact with PALLADIA. Keep children away from feces urine or vomit of treated dogs. To avoid exposure to drug wash hands with soap and water after administering PALLADIA and wear protective gloves to prevent direct contact with feces urine vomit and broken or moistened PALLADIA tablets. Place all waste materials in a plastic bag and seal before general disposal. If eyes are accidentally exposed to the drug rinse eyes with water immediately. In case of accidental ingestion by a person seek medical advice immediately show the package insert or label to the physician. Gastrointestinal discomfort such as vomiting or diarrhea may occur if this drug is accidentally ingested.

Pregnant women women who may become pregnant or nursing mothers should pay special attention to these handling precautions. (See handling instructions above.) PALLADIA like other drugs in its class prevents the formation of new blood vessels in tumors. In a similar manner PALLADIA may affect blood vessel formation in the developing fetus and may harm an unborn baby (cause birth defects). For pregnant women accidental ingestion of PALLADIA may have adverse effects on pregnancy. - DIRECTIONS:Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized if needed to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks thereafter. PALLADIA may be administered with or without food. Do not split tablets. - INGREDIENTS:Toceranib Phosphate. - MATERIAL/COMP:Solid (e.g. Chews Tablet Toy) - STORAGE/DISPOSAL REQ:Store at controlled room temperature 20 to 25 C (68 to 77 F). - HEIGHT(INCHES): 1.000 - WIDTH(INCHES):1.000 - LENGTH(INCHES):1.000

Ingredients

Toceranib Phosphate.

Dosage & Directions

Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets.

Cautions & Warnings

PALLADIA may cause vascular dysfunction which can lead to edema and thromboembolism, including pulmonary thromboembolism. Discontinue drug until clinical signs and clinical pathology have normalized. To assure vasculature homeostasis, wait at least 3 days after stopping drug before performing surgery. Do not use in dogs used for breeding, or for pregnant or lactating bitches. Potential Side Effects: Diarrhea, appetite loss, lameness, weight loss, bloody stool Serious and sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in dogs treated with PALLADIA (see Adverse Reactions). If gastrointestinal ulceration is suspected, stop drug administration and treat appropriately. Human warnings: NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Children should not come in contact with PALLADIA. Keep children away from feces, urine, or vomit of treated dogs. To avoid exposure to drug, wash hands with soap and water after administering PALLADIA and wear protective gloves to prevent direct contact with feces, urine, vomit, and broken or moistened PALLADIA tablets. Place all waste materials in a plastic bag and seal before general disposal. If eyes are accidentally exposed to the drug, rinse eyes with water immediately. In case of accidental ingestion by a person, seek medical advice immediately, show the package insert or label to the physician. Gastrointestinal discomfort such as vomiting or diarrhea may occur if this drug is accidentally ingested. Pregnant women, women who may become pregnant, or nursing mothers should pay special attention to these handling precautions. (See handling instructions above.) PALLADIA, like other drugs in its class, prevents the formation of new blood vessels in tumors. In a similar manner, PALLADIA may affect blood vessel formation in the developing fetus and may harm an unborn baby (cause birth defects). For pregnant women, accidental ingestion of PALLADIA may have adverse effects on pregnancy.

Storage & Disposal

Store at controlled room temperature 20° to 25° C (68° to 77° F).